U.S. Markets closed

LogicBio Therapeutics, Inc. (LOGC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.64-0.11 (-1.91%)
At close: 4:00PM EDT

LogicBio Therapeutics, Inc.

65 Hayden Avenue
2nd Floor
Lexington, MA 02421
United States
617 245 0399
http://www.logicbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Mr. Frederic Chereau M.B.A.Pres, CEO & Director632.9kN/A1967
Dr. Mark A. KayIndependent Co-Founder & Director102.5kN/A1958
Mr. Seokho Yoon Esq.Chief Admin. Officer, Gen. Counsel & Corp. Sec.415.24kN/A1978
Dr. Leszek Lisowski Ph.D.Co-FounderN/AN/AN/A
Dr. Adi Barzel Ph.D.Co-FounderN/AN/AN/A
Mr. Matthias B. JafféChief Financial OfficerN/AN/A1968
Dr. Matthias HebbenGlobal VP & Head of Technology Devel.N/AN/AN/A
Mr. Brian LuqueAssociate Director of Investor RelationsN/AN/AN/A
Dr. Daniel J. Gruskin M.D.Sr. VP & Head of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Lexington, Massachusetts.

Corporate Governance

LogicBio Therapeutics, Inc.’s ISS Governance QualityScore as of October 6, 2020 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.